Grace Therapeutics vs Rocket Pharmaceuticals
GRCE and RCKT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRCE and RCKT compare
Rocket Pharmaceuticals is the larger company, worth 6.4 times as much as Grace Therapeutics ($232M against $36.2M).
Grace Therapeutics scores higher on the StockData Score (8 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRCE | RCKT |
|---|---|---|
| Size and price | ||
| Market cap | $36.2M | $232M |
| Share price | $1.72 | $2.11 |
| Change, 1 year | −43.8% | −30.8% |
| Change, 5 years | −79.2% | −91.1% |
| Beta (5Y) | 0.64 | 2.32 |
| Employees | 5 | 202 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.8× | 0.6× (better) |
| FCF yield | – | −73.6% |
| Profitability | ||
| Return on equity | −36.2% | −4.8% (better) |
| Return on invested capital | −39.3% (better) | −180% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −101.3× |
| Current ratio | 11.47 (better) | 9.24 |
| Altman Z-score | 3.57 (better) | −2.72 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 18.8% | 90.9% |
| Held by insiders | 37.8% | 22.3% |
| Insider net buying, 12 months | $839K (better) | −$934K |
| Short interest, % of float | 12.7% | 19.0% |
Go deeper
- GRCE stock overview
- GRCE income statement
- GRCE valuation and score
- RCKT stock overview
- RCKT income statement
- RCKT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.